DexlansoprazoleThird Party Manufacturing in India

Dexlansoprazole is a proton pump inhibitor that belongs to the substituted benzimidazole class of antisecretory compounds. It is the R-enantiomer of lansoprazole and suppresses gastric acid secretion by specific inhibition of the H+, K+-ATPase enzyme system at the secretory surface of gastric parietal cells. This enzyme complex is responsible for the final step of gastric acid production, where hydrogen ions are exchanged for potassium ions across the parietal cell membrane. Dexlansoprazole accumulates in the acidic environment of the parietal cell canaliculi, where it is protonated and converted to its active sulfenamide form. This active species forms covalent disulfide bonds with cysteine residues on the proton pump, resulting in irreversible inhibition of acid secretion. Because the H+, K+-ATPase is the terminal step in acid production, dexlansoprazole effectively blocks both basal and stimulated gastric acid secretion regardless of the stimulus. The dual delayed-release formulation of dexlansoprazole provides two distinct release phases, extending the duration of acid suppression and allowing once-daily dosing with flexible timing relative to meals. Gastric acid secretion resumes only after new proton pump molecules are synthesized, giving the drug a longer duration of action than many other PPIs.

Therapeutic Uses

Dexlansoprazole is indicated for the treatment of:

• Erosive Esophagitis: Dexlansoprazole is FDA-approved for healing and maintaining healing of erosive esophagitis, a condition caused by chronic acid damage to the esophageal lining.
• Gastroesophageal Reflux Disease (GERD): It is highly effective in treating heartburn and other symptoms of GERD, including acid regurgitation and difficulty swallowing.
• Helicobacter pylori Eradication: As part of combination therapy with antibiotics, dexlansoprazole helps eradicate H. pylori infection, reducing the risk of peptic ulcer recurrence.
• Zollinger-Ellison Syndrome: It is used off-label in hypersecretory conditions where profound acid suppression is required.

Why Manufacturers Choose Dexlansoprazole

Dexlansoprazole offers Indian pharmaceutical manufacturers a differentiated PPI product in a market dominated by omeprazole, pantoprazole, and rabeprazole. The dual delayed-release technology provides a unique pharmacokinetic advantage with extended acid suppression, making it an attractive alternative for patients with persistent nighttime symptoms. Indian manufacturers with advanced oral solid dosage capabilities can leverage their expertise in modified-release formulations to produce high-quality dexlansoprazole delayed-release capsules. The molecule is well-suited for third party manufacturing arrangements targeting PCD franchise networks and export markets in the Middle East, Southeast Asia, and Africa. With established IP and USP monographs, dexlansoprazole offers a clear regulatory pathway for WHO-GMP certified facilities seeking to expand their gastrointestinal product portfolio.